TIG­IT grave­yard ex­pands as GSK drops late-stage as­set with iTeos

Last week
R&D

Watch Post-Hoc Live: Trump's 'most fa­vored na­tion' plan to cut drug prices

Last week
Pharma

Up­dat­ed: To spin off or not to spin off? Gala­pa­gos backpedals on sep­a­ra­tion plans, CEO Paul Stof­fels ex­its ear­ly

Last week
People
Cell/Gene Tx

Bay­er starts 2025 by cut­ting 2,000 jobs as it homes in on year-end re­haul tar­get

Last week
People
Pharma

Dutch biotech gets $146M for late-stage tri­als in three meta­bol­ic dis­or­ders

Last week
Financing
Startups

Phar­ma in­vestors brush off Trump’s ‘most fa­vored na­tion’ plan as stocks rise

Last week
Pharma

Lack of de­tail in Trump's drug price plan rais­es more ques­tions than an­swers

Last week
Pharma
Law

PBM over­haul and drug price ne­go­ti­a­tions make the cut in Re­pub­li­can­s' tax bill

Last week
Pharma
Law

Roche could re­think $50B US ex­pan­sion plan if new poli­cies 'har­m' op­er­a­tions

Last week
Pharma
Manufacturing

Ex­clu­sive: Patrick Hsu start­up launch­es, looks be­yond CRISPR for gene in­ser­tion tech­nol­o­gy

Last week
Startups
Cell/Gene Tx

Vir’s hep B dis­ap­point­ment, Ipsen's new Iqir­vo da­ta, plus more from #EASL25

Last week
R&D

FDA clears in vi­vo blood stem cell edit­ing tri­al; Abeon­a's $155M PRV sale

Last week
News Briefing

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Last week
Pharma

Lil­ly says fur­ther head-to-head tri­al da­ta back Zep­bound over No­vo’s We­govy

Last week
R&D

Trump says he'll sign or­der on 'most fa­vored na­tion' drug price plans Mon­day

Last week
R&D
Pharma

Makary names Vinay Prasad CBER chief; Q1 earn­ings re­port; More on “Most Fa­vored Na­tions"; and more

3 weeks ago
Weekly

Chron­ic care start­up Oma­da Health files to go pub­lic

3 weeks ago
Financing
Startups

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

3 weeks ago
Pharma
Manufacturing

As­traZeneca re­ports Phase 3 win for Imfinzi; Roche to build new man­u­fac­tur­ing site in Chi­na

3 weeks ago
News Briefing

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

3 weeks ago
R&D

Lon­za says its US-based sites are in high de­mand as phar­ma tar­iffs near

3 weeks ago
Pharma
Manufacturing

In­tro­duc­ing the new End­points pro­file ex­pe­ri­ence

3 weeks ago
Publisher's note

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

3 weeks ago
Peer Review

Corvus' ear­ly-phase atopic der­mati­tis da­ta prompt stock ral­ly

3 weeks ago
R&D
First page Previous page 3456789 Next page Last page
A service from the Financial Times